AbCellera Biologics Inc.
corporate_fare Company Profile
AbCellera Biologics Inc. (NASDAQ:ABCL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for ABCL at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- AbCellera Reports Strong 2025 Revenue Growth, Reduced Net Loss, Advances Pipeline, and Secures Patent Settlement
- AbCellera Reports Improved 2025 Financials, Strong Liquidity, and Pipeline Progress with Multiple Clinical Programs
- AbCellera's Lead Candidate ABCL635 Advances to Phase 2 Clinical Trial for Menopausal Vasomotor Symptoms
Financial Snapshot
Fiscal year ended December 31, 2025
Revenue
$75.13M
Net Income
-$146.41M
Diluted EPS
-$0.49
Op. Cash Flow
-$131.29M
Free Cash Flow
-$174.07M
Operating Income
-$217.1M
Cash & Equivalents
$128.51M
Debt / Equity
0.00×
Net Margin
-194.9%
Shares Outstanding
300.6M sh
Source: 10-K · filed 2026-02-24 · accession 0001703057-26-000012
show_chartPrice Chart
Loading chart...
feed ABCL - Filings & News (Page 2)
ABCL
Feb 24, 2026, 4:38 PM EST
Price at Filing:
$3.61
Real-time Price:
$9.73
Change:
+$6.12 (+170%)
Market Cap:
$3.165B
ABCL
Feb 24, 2026, 4:15 PM EST
Price at Filing:
$3.34
Real-time Price:
$9.73
Change:
+$6.39 (+191%)
Market Cap:
$3.165B
ABCL
Jan 14, 2026, 5:09 PM EST
Price at Filing:
$4.30
Real-time Price:
$9.73
Change:
+$5.43 (+126%)
Market Cap:
$3.165B